v3.26.1
Collaboration Agreements - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaboration revenue $ 2,451,000 $ 2,412,000 $ 5,223,000 $ 3,863,000  
Collaboration Agreements | Novartis Pharma AG          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future long-term research, development, and commercial milestone payment     530,000,000    
Upfront payments and research funding     20,000,000    
Collaboration revenue 2,400,000 $ 2,400,000 5,200,000 $ 3,900,000  
Deferred revenue current liabilities $ 4,400,000   4,400,000   $ 5,800,000
Collaboration Agreements | Novartis Pharma AG | Deferred Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaboration revenue     1,400,000    
Collaboration Agreements | Novartis Pharma AG | Reimbursable Costs          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaboration revenue     $ 3,800,000